• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于机器学习算法构建两个独立的 RAB 家族评分系统,并定义 RAB13 为肝细胞癌的新型治疗靶点。

Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma.

机构信息

Department of Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu 610041, China.

Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital of Sichuan University, Chengdu 610041, China.

出版信息

Int J Mol Sci. 2023 Feb 22;24(5):4335. doi: 10.3390/ijms24054335.

DOI:10.3390/ijms24054335
PMID:36901767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10001462/
Abstract

Hepatocellular carcinoma (HCC) remains a global health challenge with a low early diagnosis rate and high mortality. The Rab GTPase (RAB) family plays an essential role in the occurrence and progression of HCC. Nonetheless, a comprehensive and systematic investigation of the RAB family has yet to be performed in HCC. We comprehensively assessed the expression landscape and prognostic significance of the RAB family in HCC and systematically correlated these RAB family genes with tumor microenvironment (TME) characteristics. Then, three RAB subtypes with distinct TME characteristics were determined. Using a machine learning algorithm, we further established a RAB score to quantify TME features and immune responses of individual tumors. Moreover, to better evaluate patient prognosis, we established a RAB risk score as an independent prognostic factor for patients with HCC. The risk models were validated in independent HCC cohorts and distinct HCC subgroups, and their complementary advantages guided clinical practice. Furthermore, we further confirmed that the knockdown of RAB13, a pivotal gene in risk models, suppressed HCC cell proliferation and metastasis by inhibiting the PI3K/AKT signaling pathway, CDK1/CDK4 expression, and epithelial-mesenchymal transition. In addition, RAB13 inhibited the activation of JAK2/STAT3 signaling and the expression of IRF1/IRF4. More importantly, we confirmed that RAB13 knockdown enhanced GPX4-dependent ferroptosis vulnerability, highlighting RAB13 as a potential therapeutic target. Overall, this work revealed that the RAB family played an integral role in forming HCC heterogeneity and complexity. RAB family-based integrative analysis contributed to enhancing our understanding of the TME and guided more effective immunotherapy and prognostic evaluation.

摘要

肝细胞癌(HCC)仍然是一个全球性的健康挑战,其早期诊断率低,死亡率高。Ras GTPase(RAB)家族在 HCC 的发生和发展中起着至关重要的作用。然而,目前尚未对 HCC 中的 RAB 家族进行全面系统的研究。我们全面评估了 RAB 家族在 HCC 中的表达谱和预后意义,并系统地将这些 RAB 家族基因与肿瘤微环境(TME)特征相关联。然后,确定了具有不同 TME 特征的三种 RAB 亚型。我们进一步使用机器学习算法,建立了一个 RAB 评分,以量化个体肿瘤的 TME 特征和免疫反应。此外,为了更好地评估患者的预后,我们建立了一个 RAB 风险评分,作为 HCC 患者的独立预后因素。该风险模型在独立的 HCC 队列和不同的 HCC 亚组中得到了验证,并具有互补优势,指导临床实践。此外,我们进一步证实,风险模型中的关键基因 RAB13 的敲低通过抑制 PI3K/AKT 信号通路、CDK1/CDK4 表达和上皮-间充质转化,抑制 HCC 细胞增殖和转移。此外,RAB13 抑制了 JAK2/STAT3 信号的激活和 IRF1/IRF4 的表达。更重要的是,我们证实 RAB13 敲低增强了 GPX4 依赖性铁死亡的脆弱性,突出了 RAB13 作为潜在治疗靶点的重要性。总的来说,这项工作揭示了 RAB 家族在形成 HCC 异质性和复杂性方面起着不可或缺的作用。基于 RAB 家族的综合分析有助于增强我们对 TME 的理解,并指导更有效的免疫治疗和预后评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/385bdfc89398/ijms-24-04335-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/2c8d5f02a4bb/ijms-24-04335-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/794be9332478/ijms-24-04335-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/8efb82e22c9e/ijms-24-04335-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/4fb3d04d47f6/ijms-24-04335-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/1e59e121682e/ijms-24-04335-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/67917c4f3456/ijms-24-04335-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/f7db9ddd71a7/ijms-24-04335-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/3bfd101b9b63/ijms-24-04335-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/8ef728435ae9/ijms-24-04335-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/385bdfc89398/ijms-24-04335-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/2c8d5f02a4bb/ijms-24-04335-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/794be9332478/ijms-24-04335-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/8efb82e22c9e/ijms-24-04335-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/4fb3d04d47f6/ijms-24-04335-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/1e59e121682e/ijms-24-04335-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/67917c4f3456/ijms-24-04335-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/f7db9ddd71a7/ijms-24-04335-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/3bfd101b9b63/ijms-24-04335-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/8ef728435ae9/ijms-24-04335-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7b/10001462/385bdfc89398/ijms-24-04335-g010.jpg

相似文献

1
Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma.基于机器学习算法构建两个独立的 RAB 家族评分系统,并定义 RAB13 为肝细胞癌的新型治疗靶点。
Int J Mol Sci. 2023 Feb 22;24(5):4335. doi: 10.3390/ijms24054335.
2
Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.构建并验证 IRF4 风险评分模型,以预测肝细胞癌的预后和免疫治疗反应。
Int Immunopharmacol. 2022 Dec;113(Pt A):109411. doi: 10.1016/j.intimp.2022.109411. Epub 2022 Nov 8.
3
A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.一种基于肿瘤发生和免疫浸润指导策略的细胞衰老相关分类器可预测肝细胞癌的预后、免疫治疗反应和候选药物。
Front Immunol. 2022 Nov 15;13:974377. doi: 10.3389/fimmu.2022.974377. eCollection 2022.
4
APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.APLN 通过激活 PI3K/Akt 通路促进肝癌发生,是一个有潜力的药物靶点。
Theranostics. 2019 Jul 9;9(18):5246-5260. doi: 10.7150/thno.34713. eCollection 2019.
5
Rab11a regulates MMP2 expression by activating the PI3K/AKT pathway in human hepatocellular carcinoma cells.Rab11a 通过激活 PI3K/AKT 通路调节人肝癌细胞中 MMP2 的表达。
Pathol Res Pract. 2020 Sep;216(9):153046. doi: 10.1016/j.prp.2020.153046. Epub 2020 Jun 1.
6
Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.超重/肥胖相关的转录组特征与肝细胞癌的临床结局、免疫微环境和治疗反应相关。
Front Endocrinol (Lausanne). 2023 Jan 12;13:1061091. doi: 10.3389/fendo.2022.1061091. eCollection 2022.
7
The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.长链非编码 RNA PTTG3P 通过上调 PTTG1 和激活 PI3K/AKT 信号通路促进肝癌细胞生长和转移。
Mol Cancer. 2018 May 26;17(1):93. doi: 10.1186/s12943-018-0841-x.
8
SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.SPAG5 通过 PI3K/AKT 通路与 CEP55 相互作用,在肝癌中发挥致癌活性。
Mol Cancer. 2018 Aug 8;17(1):117. doi: 10.1186/s12943-018-0872-3.
9
Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.基于肝癌微环境构建风险评分预后模型。
World J Gastroenterol. 2020 Jan 14;26(2):134-153. doi: 10.3748/wjg.v26.i2.134.
10
PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway.PES1 通过 PI3K/AKT 通路促进肝癌的增殖和肿瘤发生。
Life Sci. 2019 Feb 15;219:182-189. doi: 10.1016/j.lfs.2018.12.054. Epub 2019 Jan 8.

引用本文的文献

1
DDX42 Enhances Hepatocellular Carcinoma Cell Proliferation, Radiation and Sorafenib Resistance via Regulating GRB2 RNA Maturation and Activating PI3K/AKT Pathway.DDX42通过调节GRB2 RNA成熟和激活PI3K/AKT通路增强肝癌细胞增殖、辐射抗性和索拉非尼抗性。
J Cell Mol Med. 2025 Aug;29(16):e70793. doi: 10.1111/jcmm.70793.
2
Identification and validation of Rab GTPases RAB13 as biomarkers for peritoneal metastasis and immune cell infiltration in colorectal cancer patients.鉴定和验证 Rab GTPases RAB13 作为结直肠癌患者腹膜转移和免疫细胞浸润的生物标志物。
Front Immunol. 2024 Aug 13;15:1403008. doi: 10.3389/fimmu.2024.1403008. eCollection 2024.
3

本文引用的文献

1
Turning cold tumors hot: from molecular mechanisms to clinical applications.使冷肿瘤变热:从分子机制到临床应用。
Trends Immunol. 2022 Jul;43(7):523-545. doi: 10.1016/j.it.2022.04.010. Epub 2022 May 25.
2
Rab13 Sustains Breast Cancer Stem Cells by Supporting Tumor-Stroma Cross-talk.Rab13 通过支持肿瘤-基质细胞串扰维持乳腺癌干细胞。
Cancer Res. 2022 Jun 6;82(11):2124-2140. doi: 10.1158/0008-5472.CAN-21-4097.
3
RNF115 Inhibits the Post-ER Trafficking of TLRs and TLRs-Mediated Immune Responses by Catalyzing K11-Linked Ubiquitination of RAB1A and RAB13.
Function and regulation of Rab GTPases in cancers.
Rab GTPases 在癌症中的功能和调控。
Cell Biol Toxicol. 2024 May 2;40(1):28. doi: 10.1007/s10565-024-09866-5.
RNF115 通过催化 RAB1A 和 RAB13 的 K11 连接泛素化来抑制 TLRs 的 ER 后转运和 TLRs 介导的免疫反应。
Adv Sci (Weinh). 2022 May;9(16):e2105391. doi: 10.1002/advs.202105391. Epub 2022 Mar 28.
4
Principal Component Analysis (PCA).主成分分析(PCA)。
Tunis Med. 2021;99(4):383-389.
5
Necroptosis-Related lncRNAs: Predicting Prognosis and the Distinction between the Cold and Hot Tumors in Gastric Cancer.坏死性凋亡相关长链非编码RNA:预测胃癌预后及区分冷肿瘤与热肿瘤
J Oncol. 2021 Nov 8;2021:6718443. doi: 10.1155/2021/6718443. eCollection 2021.
6
The Regulation of Rab GTPases by Phosphorylation.Rab GTPases 的磷酸化调节。
Biomolecules. 2021 Sep 10;11(9):1340. doi: 10.3390/biom11091340.
7
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.非酒精性脂肪性肝病相关肝细胞癌:现有和新兴治疗选择的安全性和疗效。
J Hepatol. 2022 Feb;76(2):446-457. doi: 10.1016/j.jhep.2021.09.007. Epub 2021 Sep 20.
8
Liver cirrhosis.肝硬化。
Lancet. 2021 Oct 9;398(10308):1359-1376. doi: 10.1016/S0140-6736(21)01374-X. Epub 2021 Sep 17.
9
Immunotherapy in Hepatocellular Carcinoma.肝细胞癌的免疫治疗。
Curr Treat Options Oncol. 2021 Aug 23;22(10):87. doi: 10.1007/s11864-021-00886-5.
10
Genomic Landscape of HCC.肝癌的基因组图谱
Curr Hepatol Rep. 2020 Dec;19(4):448-461. doi: 10.1007/s11901-020-00553-7. Epub 2020 Nov 10.